MedTrace Logo

Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients

NCT04520373 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-10-14

No results posted yet for this study

Summary

The purpose of this research study is to investigate the safety and potential therapeutic effects of autologous, culture-expanded, adipose derived mesenchymal stem cell intrathecal injections in the treatment of spinal cord injury.

Conditions

  • Spinal Cord Injuries
  • Paralysis

Interventions

OTHER

Best Medical Management: Occupational and Physical Therapy

Observation while undergoing Occupational and Physical Therapy for 6 months

BIOLOGICAL

Autologous, Adipose Derived Mesenchymal Stem Cells

The mesenchymal stem cells will be collected and expanded from the patients' adipose tissue.

Sponsors & Collaborators

Principal Investigators

  • Wenchun Qu, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-25
Primary Completion
2026-07-31
Completion
2026-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04520373 on ClinicalTrials.gov